The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

European shares European shares were higher on Monday as investors reacted to U.S. President Donald Trump delaying the roll ...

Zealand Pharma A/S ADR stock grades by Barron's. View ZLDPY fundamental and sentiment analysis powered by MarketGrader.

On Tuesday, Deutsche Bank (ETR:DBKGn) analyst Emmanuel Papadakis revised the price target for Zealand Pharma A/S (NASDAQ:ZEAL:DC) (NASDAQ: ZEAL), lowering it to DKK485.00 from the previous DKK750.00.

In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other Friday’s top performers. The stock market finished the trading week in the ...

Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David ...

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the ...

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer. Johnson will join the executive team to lead regulatory and development strategies. His ...